Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
| Revenue (Most Recent Fiscal Year) | $44.46B |
| Net Income (Most Recent Fiscal Year) | $6.02B |
| PE Ratio (Current Year Earnings Estimate) | 10.61 |
| PE Ratio (Trailing 12 Months) | 11.70 |
| PEG Ratio (Long Term Growth Estimate) | 1.00 |
| Price to Sales Ratio (Trailing 12 Months) | 2.47 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.56 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 9.09 |
| Pre-Tax Margin (Trailing 12 Months) | 16.78% |
| Net Margin (Trailing 12 Months) | 14.56% |
| Return on Equity (Trailing 12 Months) | 17.15% |
| Return on Assets (Trailing 12 Months) | 9.80% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.37 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.69 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.16 |
| Inventory Turnover (Trailing 12 Months) | 1.22 |
| Book Value per Share (Most Recent Fiscal Quarter) | $33.20 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.94 |
| Earnings per Share (Most Recent Fiscal Year) | $3.85 |
| Diluted Earnings per Share (Trailing 12 Months) | $2.80 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 2.45B |
| Free Float | 2.43B |
| Market Capitalization | $118.75B |
| Average Volume (Last 20 Days) | 2.31M |
| Beta (Past 60 Months) | 0.50 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 14.04% |
| Annual Dividend (Based on Last Quarter) | $1.60 |
| Dividend Yield (Based on Last Quarter) | 3.30% |